Patents by Inventor Tine Elisabeth Gottschalk Bøving

Tine Elisabeth Gottschalk Bøving has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Manufacture of degarelix
    Patent number: 11510962
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, a and processes for providing this lyophilized degarelix drug substance.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: November 29, 2022
    Assignee: Ferring B.V.
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • Manufacture of Degarelix
    Patent number: 11260102
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: March 1, 2022
    Assignee: Ferring B.V.
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • LIQUID FORMULATIONS OF GLUCAGON ANALOGUES
    Publication number: 20210283053
    Abstract: The present invention relates to formulations of glucagon analogues, or a pharmaceutically acceptable salt thereof and/or a derivative thereof; and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable aqueous liquid formulations of glucagon analogues comprising combinations of excipients that make them suitable for long term storage as liquids, and are capable of use in single-dose (SD) or multi-dose (MD) formulations.
    Type: Application
    Filed: March 16, 2021
    Publication date: September 16, 2021
    Inventors: Jesper Skodborg VILLADSEN, Tine Elisabeth Gottschalk BØVING
  • MANUFACTURE OF DEGARELIX
    Publication number: 20210138024
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, a and processes for providing this lyophilized degarelix drug substance.
    Type: Application
    Filed: January 21, 2021
    Publication date: May 13, 2021
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • MANUFACTURE OF DEGARELIX
    Publication number: 20210077564
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Application
    Filed: July 30, 2020
    Publication date: March 18, 2021
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • Manufacture of Degarelix
    Patent number: 10765721
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: September 8, 2020
    Assignee: Ferring B.V
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • MANUFACTURE OF DEGARELIX
    Publication number: 20190224271
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Application
    Filed: December 19, 2018
    Publication date: July 25, 2019
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • Manufacture of Degarelix
    Patent number: 10172906
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: January 8, 2019
    Assignee: Ferring B.V.
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • MANUFACTURE OF DEGARELIX
    Publication number: 20170319644
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Application
    Filed: January 31, 2017
    Publication date: November 9, 2017
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • Manufacture of degarelix
    Patent number: 9592266
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: March 14, 2017
    Assignee: FERRING B.V.
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • MANUFACTURE OF DEGARELIX
    Publication number: 20150141337
    Abstract: The present invention provides methods for producing a lyophilized degarelix product which, upon reconstitution with water for injection in an amount of 20 mg/ml, shows a viscosity of up to 15 mPas. The present invention also provides a lyophilized degarelix drug substance which shows, upon dissolution in water in an amount of 20 mg/ml, a viscosity of up to 3.2 mPas, and processes for providing this lyophilized degarelix drug substance.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 21, 2015
    Applicant: Ferring B.V.
    Inventors: Grégoire Schwach, Anders Nilsson, Tine Elisabeth Gottschalk Bøving, Jon Holbech Rasmussen, Birgitta Mörnstam, Anders Tsirk, Ulf Annby, Jens Fomsgaard
  • Stable formulations of peptides
    Patent number: 8748376
    Abstract: Stable pharmaceutical composition comprising insulinotropic peptide.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: June 10, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Svend Ludvigsen, Morten Schlein, Tine Elisabeth Gottschalk Bøving, Claude Bonde, Anne-Mette Lilleøre, Dorthe Kot Engelund, Bjarne Rønfeldt Nielsen
  • Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
    Patent number: 8158583
    Abstract: Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide.
    Type: Grant
    Filed: May 12, 2009
    Date of Patent: April 17, 2012
    Assignee: Novo Nordisk A/S
    Inventors: Liselotte Bjerre Knudsen, Kristian Tage Hansen, Dorthe Kot Engelund, Svend Ludvigsen, Lars Hansen, Claude Bonde, Ejvind Jensen, Tine Elisabeth Gottschalk Bøving, Morten Schlein